SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds And Novel Approach For The Treatment Of Chronic Epilepsies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced new data presented at the American Epilepsy Society (AES) Annual Meeting that reveal a novel mechanism and approach for the treatment of status epilepticus (SE) and identify new, orally bioavailable compounds that may lead to improved therapies for chronic epilepsies.

Help employers find you! Check out all the jobs and post your resume.